Disease · MONDO_0021054

bone sarcoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. bone sarcoma. Diseases, record MONDO_0021054. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0021054

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: bone sarcoma; Open Targets
Open Targets ID: MONDO_0021054; Open Targets
Other names: osseous sarcoma, sarcoma of bone, sarcoma of the bone, skeletal sarcoma; Open Targets
Disease Ontology: DOID:0080639; Disease Ontology
NCI Thesaurus: C9312; NCI Thesaurus
Orphanet: ORPHA:223727; Orphanet
Highest stage of its drugs: Approval, for 1 of its 51 drugs, from DailyMed; Open Targets

Drugs51

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
DOXORUBICIN HYDROCHLORIDE	CHEMBL359744	Small molecule	Approval	DailyMed	2	1	1	Drugs and targets
RIDAFOROLIMUS	CHEMBL2103839	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
GEMCITABINE	CHEMBL888	Small molecule	Phase 2	ClinicalTrials.gov	7	7	7	Drugs and targets
IFOSFAMIDE	CHEMBL1024	Small molecule	Phase 2	ClinicalTrials.gov	5	5	5	Drugs and targets
DOCETAXEL	CHEMBL3545252	Small molecule	Phase 2	ClinicalTrials.gov	4	4	4	Drugs and targets
DOXORUBICIN	CHEMBL53463	Small molecule	Phase 2	ClinicalTrials.gov	4	4	4	Drugs and targets
ASCORBIC ACID	CHEMBL196	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
RIVOCERANIB	CHEMBL3186534	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
TEMSIROLIMUS	CHEMBL1201182	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets

1 to 10 of 51

See all 51 drugs

Targets71

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
KDR	Vascular endothelial growth factor receptor	7	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3791	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	6	Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2324	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	5	Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2321	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	5	Stem cell growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3815	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor	5	Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/5159	Drugs and targets
TOP2A	DNA topoisomerase 2-alpha	5	DNA topoisomerase II alpha inhibitor; DNA topoisomerase II inhibitor	Approval	https://conductscience.org/library/genes/7153	Drugs and targets
PDCD1	Programmed cell death protein 1	4	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Phase 2	https://conductscience.org/library/genes/5133	Drugs and targets
RET	Proto-oncogene tyrosine-protein kinase receptor Ret	3	Tyrosine-protein kinase receptor RET inhibitor	Phase 2	https://conductscience.org/library/genes/5979	Drugs and targets
TUBA1A	Tubulin	3	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	3	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/10376	Drugs and targets

1 to 10 of 71

See all 71 targets

Trials42

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01016015	Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma	Phase 2	178	2015-07-30	Metastatic Osteosarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Osteosarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma	CIXUTUMUMAB, TEMSIROLIMUS	Its record names the disease	ClinicalTrials.gov
NCT02301039	SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas	Phase 2	144	2020-09-29	Soft Tissue Sarcoma, Bone Sarcoma	PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00767819	Treatment of Patients With RAD001 With Progressive Sarcoma	Phase 2	71	2019-04-01	Progressive Sarcoma	EVEROLIMUS	Its record names the disease	ClinicalTrials.gov
NCT01896505	A Phase I Trial to Assess the Effects of Food and Formulation on PK of KPT-330 in Patients With Sarcoma	Phase 1	54	2024-01-08	Sarcoma	SELINEXOR	Its record names the disease	ClinicalTrials.gov
NCT00949325	Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma	Phase 1/2	24	2019-03-11	Sarcoma	DOXORUBICIN, TEMSIROLIMUS	Its record names the disease	ClinicalTrials.gov
NCT02756845	Study of Talimogene Laherparepvec In Children With Advanced Non CNS Tumors	Phase 1	15	2024-02-05	Advanced Non CNS Tumors	TALIMOGENE LAHERPAREPVEC	Its record names the disease	ClinicalTrials.gov
NCT03468075	Gemcitabine Plus Ascorbate for Sarcoma in Adults	Phase 2	10	2020-12-10	Sarcoma, Soft Tissue Sarcoma, Unresectable Soft Tissue Sarcoma, Metastatic Bone Tumor, Bone Sarcoma	ASCORBIC ACID, GEMCITABINE	Its record names the disease	ClinicalTrials.gov
NCT00544778	Combination Chemotherapy and Dexrazoxane Followed by Surgery and Radiation Therapy in Treating Patients With Advanced Soft Tissue Sarcoma or Recurrent Bone Sarcoma	Phase 2	7	2014-08-28	Sarcoma	DEXRAZOXANE HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE, IFOSFAMIDE, IRINOTECAN HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT00880542	Sorafenib and Ifosfamide in Treating Patients With High-Grade Soft Tissue Sarcoma or Bone Sarcoma That Can Be Removed by Surgery	Phase 2	7	2011-05-10	Sarcoma	IFOSFAMIDE, SORAFENIB	Its record names the disease	ClinicalTrials.gov
NCT00538239	Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus)(8669-011 AM6)	Phase 3	711		Metastatic Soft-Tissue Sarcomas, Metastatic Bone Sarcomas	RIDAFOROLIMUS	Its record names the disease	ClinicalTrials.gov

1 to 10 of 42

See all 42 trials

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Cohort A1: Talimogene Laherparepvec (TVEC) - Aged 12 to ≤ 21 Years vs Cohort B1: Talimogene Laherparepvec (TVEC) - Aged 2 to < 12 Years: deaths from any cause	12 of 13	2 of 2	15	NCT02756845	Trial comparisons
Cohort A1: Talimogene Laherparepvec (TVEC) - Aged 12 to ≤ 21 Years vs Cohort B1: Talimogene Laherparepvec (TVEC) - Aged 2 to < 12 Years: serious adverse events	5 of 13	1 of 2	15	NCT02756845	Trial comparisons

Papers from its trials29

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
30217671	RESULT	1	PubMed
23715582	RESULT	1	PubMed
23382028	RESULT	1	PubMed
19451433	RESULT	1	PubMed
41836677	DERIVED	1	PubMed
40267388	DERIVED	1	PubMed
39356980	DERIVED	1	PubMed
38031088	DERIVED	1	PubMed
37934000	DERIVED	1	PubMed
37769113	DERIVED	1	PubMed

1 to 10 of 29

See all 29 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0021054

GET https://conductscience.org/api/diseases/v1/MONDO_0021054/drugs?page=2

API reference For AI assistants